Department of Neurosurgery, St Olavs University Hospital, Trondheim, Norway.
PLoS One. 2011;6(12):e28592. doi: 10.1371/journal.pone.0028592. Epub 2011 Dec 9.
Studies indicate that acquired deficits negatively affect patients' self-reported health related quality of life (HRQOL) and survival, but the impact of HRQOL deterioration after surgery on survival has not been explored.
Assess if change in HRQOL after surgery is a predictor for survival in patients with glioblastoma.
Sixty-one patients with glioblastoma were included. The majority of patients (n = 56, 91.8%) were operated using a neuronavigation system which utilizes 3D preoperative MRI and updated intraoperative 3D ultrasound volumes to guide resection. HRQOL was assessed using EuroQol 5D (EQ-5D), a generic instrument. HRQOL data were collected 1-3 days preoperatively and after 6 weeks. The mean change in EQ-5D index was -0.05 (95% CI -0.15-0.05) 6 weeks after surgery (p = 0.285). There were 30 patients (49.2%) reporting deterioration 6 weeks after surgery. In a Cox multivariate survival analysis we evaluated deterioration in HRQOL after surgery together with established risk factors (age, preoperative condition, radiotherapy, temozolomide and extent of resection).
There were significant independent associations between survival and use of temozolomide (HR 0.30, p = 0.019), radiotherapy (HR 0.26, p = 0.030), and deterioration in HRQOL after surgery (HR 2.02, p = 0.045). Inclusion of surgically acquired deficits in the model did not alter the conclusion.
Early deterioration in HRQOL after surgery is independently and markedly associated with impaired survival in patients with glioblastoma. Deterioration in patient reported HRQOL after surgery is a meaningful outcome in surgical neuro-oncology, as the measure reflects both the burden of symptoms and treatment hazards and is linked to overall survival.
研究表明,获得性缺陷会对患者的自我报告健康相关生活质量(HRQOL)和生存产生负面影响,但手术治疗后 HRQOL 恶化对生存的影响尚未得到探索。
评估手术治疗后 HRQOL 的变化是否可预测胶质母细胞瘤患者的生存情况。
共纳入 61 例胶质母细胞瘤患者。大多数患者(n=56,91.8%)采用神经导航系统进行手术,该系统利用 3D 术前 MRI 和更新的术中 3D 超声体积来指导切除。使用欧洲五维健康量表(EQ-5D)评估 HRQOL,这是一种通用工具。在术前 1-3 天和术后 6 周收集 HRQOL 数据。术后 6 周时,EQ-5D 指数平均变化为-0.05(95%CI-0.15-0.05)(p=0.285)。术后 6 周时,有 30 例(49.2%)患者报告 HRQOL 恶化。在多变量 Cox 生存分析中,我们评估了手术后 HRQOL 的恶化情况,同时评估了已确定的风险因素(年龄、术前情况、放疗、替莫唑胺和切除范围)。
生存与替莫唑胺的使用(HR 0.30,p=0.019)、放疗(HR 0.26,p=0.030)和手术后 HRQOL 恶化(HR 2.02,p=0.045)有显著的独立相关性。在模型中纳入手术获得的缺陷并没有改变这一结论。
手术后 HRQOL 的早期恶化与胶质母细胞瘤患者的生存受损独立且显著相关。手术后患者报告的 HRQOL 恶化是手术神经肿瘤学中有意义的结果,因为该测量既反映了症状负担和治疗风险,又与总体生存相关。